Class Period: Feb. 23, 2022 – Dec. 17, 2024 Lead Plaintiff Deadline: Feb. 21, 2025 Visit: Contact the Firm Now: ... 844-916-0895 Probe Into AstraZeneca's China Operations The probe conducted by China regulators, which reportedly centers on allegations that AstraZeneca employees improperly imported cancer medications like Enhertu and Imjudo from Hong Kong into mainland China and mishandled patient data, has been compounded by a broader investigation into a large-scale health insurance fraud case. The confluence of these issues has raised serious concerns among investors about the potential impact on the company's regional sales and overall financial performance. The situation escalated with the arrest of Leon Wang, AstraZeneca's Executive Vice President International and China President.